Drug Trial Radar · NCT07213349
Daridorexant for Alzheimer Disease Prevention
Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Oct 14, 2025
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Douglas Mental Health University InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Weston Family Foundation
- First posted
- Oct 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease. The trial is preventive and is open to participants who do not have Alzheimer's disease dementia, regardless of whether or not they experience sleep problems.
Conditions
- Alzheimer Disease (AD)
Interventions
Daridorexant 50 mgDrug
Study drug (Daridorexant 50 mg) taken orally each night 30 minutes before bedtime, for the 1 year duration of the study
PlaceboDrug
Study drug (Placebo) will be taken orally each night, 30 minutes before bedtime, for the 1 year duration of the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in plasma p-tau217/np-tau217 ratioTime frame: baseline up to estimated 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre StoP-Alzheimer (Douglas Mental Health University Institute - Research Centre)
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.